Advertisement
Advertisement

TheBodyPRO.com covers CROI 2014

What Major HIV Research Developments Does 2014 Hold in Store?

April 4, 2014

 4/8 

Richard Elion

Simpler Regimens and Less Frequent Doses

"I think there's an interesting paradigm developing in HIV, whether we're going to see the further development and refinement of single-tablet regimens that are once-daily, with great tolerability. The cobicistat-assisted darunavir, the elvitegravir-cobicistat have already been great and the coming of dolutegravir and abacavir/3TC are all very exciting options.

"At the same time, there's an emerging second stream of agents that might be given once a month, or agents that might be given once every two months. So the issue about what will be better for keeping people who are in care, and keeping people engaged -- whether it's less frequent dosing regimens or simple, easy, well-tolerated once daily -- that's something that I'm looking forward to seeing data about."

-- Richard Elion, Director of Clinical Research, Whitman Walker Health.






This article was provided by TheBodyPRO.com. It is a part of the publication The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014).
 


 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement
Advertisement